# John Cox

> John G. Cox is president, chief executive officer and a director of Dyne Therapeutics. His career spans manufacturing and technical operations at Biogen, leadership of the Bioverativ spin-off and its sale to Sanofi, and CEO roles at Torque Therapeutics and Repertoire Immune Medicines. Atlas Venture also lists him as an adviser.

- **Role:** President and Chief Executive Officer at Dyne Therapeutics
- **Organizations:** Dyne Therapeutics, Atlas Venture, Biogen, Bioverativ, Torque Therapeutics, Repertoire Immune Medicines, Repligen, Minovia Therapeutics, Canopy Immuno-Therapeutics, Covance Biotech / Diosynth, American Home Products / Wyeth
- **Education:** B.S. in Biology, Arizona State University, M.S. in Cell Biology, California State University, MBA in Finance, University of Michigan - Stephen M. Ross School of Business
- **Known for:** Led Bioverativ through its independent launch and approximately $11.6 billion acquisition agreement with Sanofi., Bioverativ reached approximately $1.1 billion in global sales and nearly 500 employees during his leadership., Led global manufacturing, supply chain, technical development, quality and engineering functions at Biogen.

## Career timeline

- **1993-2000** — Operational roles at American Home Products / Wyeth in technology transfer, validation and purification.
- **2000-2003** — Operational roles at Covance Biotech / Diosynth.
- **2003** — Joined Biogen.
- **2010** — Became Executive Vice President of Pharmaceutical Operations & Technology at Biogen.
- **2013** — Appointed to the Repligen board.
- **2016** — Led preparations to spin off a Biogen business as Bioverativ.
- **2017** — Led Bioverativ as an independent public company.
- **2018** — Led Bioverativ during its approximately $11.6 billion sale to Sanofi.
- **2019** — Executive chairman of Torque from January, then CEO from September.
- **2020-2022** — CEO and director of Repertoire Immune Medicines from January 2020 through November 2022.
- **2024** — Appointed president, CEO and director of Dyne on March 25.

## Achievements

- Led Bioverativ through its independent launch and approximately $11.6 billion acquisition agreement with Sanofi.
- Bioverativ reached approximately $1.1 billion in global sales and nearly 500 employees during his leadership.
- Led global manufacturing, supply chain, technical development, quality and engineering functions at Biogen.
- Repertoire closed a $189 million Series B financing during his CEO tenure in April 2021.

## Latest updates

- **2026-09** — Appeared as Dyne president and CEO alongside CFO Erick Lucera at the Morgan Stanley investor conference on September 14.
- **2026-07** — Signed Dyne’s second-quarter certification as president and CEO on July 29.

## Links

- LinkedIn: https://www.linkedin.com/in/john-cox-g

---

Profile page: https://yespress.io/john-cox
Published by YesPress — https://yespress.io
Last updated: 2026-10-23